Testing Zasocitinib in Adults With Active Psoriatic Arthritis
Tests zasocitinib against placebo in adults with active psoriatic arthritis not yet treated with biologics.
Plain-language title generated from the registry record
Registry title: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Key facts
- Where
- Tallinn and Tartu Linn, EstoniaSee the 5 sites
- Phase
- Phase 3
Where in Estonia
- Center for Clinical and Basic Research ASTallinn, EstoniaNo longer taking part
- Innomedica OÜTallinn, EstoniaNo longer taking part
- North Estonia Medical Centre FoundationTallinn, EstoniaNo longer taking part
- Kliiniliste Uuringute Keskus OÜTartu Linn, EstoniaNo longer taking part
- MediTrials OÜTartu Linn, EstoniaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT06671483EU 2024-513111-27-00
- Record updated
- 14 October 2026
- Original description
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).Read full original descriptionShow less
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.
The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Inclusion: Age:; The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age; Disease Characteristics:; The participant has a diagnosis of PsA; The participant must have signs and symptoms of PsA for at least 3 months prior to screening; The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria); The participant has active arthritis as shown by a minimum of >=3 tender joints in TJC68 and >=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits; The participant has at least 1 active lesion of plaque PsO >=2 cm in diameter, or any nail or nail bed changes characteristic of PsO; Medications for PsA:; The participant has had at least one of the following:; Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union [EU]/ European Economic Area [EEA]), OR; Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Exclusion: The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO); The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia; PsA and PsO:.